|
|
||||||||
August 2009
Special
Edition |
|
|||||||
In This Issue
· Dr. McGuckin – 1st Leading Embryonic Researcher To Tell Truth · Singapore – Friendliest to Embryonics in the World · USA – Embyronic Researcher ONLY one To Tell Truth Science Advisory Board
Roberto Jorge Fernandez
Vińa, MD Honorary Professor University Maimonides Argentina Honorary Professor University of Beijing, China Shimon Slavin, MD Professor of Medicine Medical & Scientific Director Carlos Lima, MD Zannos G. Grekos, MD Kitipan V. Arom, MD,
PhD, FACS, FACC, FACCP, FRCST Don Margolis www.repairstemcells.com |
Special “Embryonic Hoax” IssueGeron Embryonic Clinical Trial
Proven a Hoax---Exactly as Don Margolis Predicted
By David Granovsky, Editor In
January, reporters excitedly flooded the world media with stories on the
‘first’ embryonic stem cell clinical trial.
Embryonic advocates celebrated this ridiculous assertion that a real FDA
approved embryonic clinical trial would be held “early this summer.” Every “medical”
reporter in every major American city newspaper with a minimal knowledge of
the limitations of embryonic stem cells for treatment and an earful of
misinformation was instructed to “play it up”…and play it up they did. The only man in the world to vocally
and adamantly dispute this fraud was Don Margolis; who began his condemnation
of the fiasco starting the day of the announcement. Mr
Margolis was the only person to point out that Geron has a lengthy track
record of such stock manipulation, “having
made ten previous announcements of upcoming trials over the past five years –
none of which has ever happened.” He stated
that the public (and the truth) would be better served and a very different
story would be told if the misinformed reporters were to further research this
‘boywho-cried-wolf’ company. “A half-hour’s research would enlighten
them that the true purpose of the announcement was to pump up the stock’s
price over 35% …” Scientists
whom to date had no positive results from embryonic research for treatments and
academic institutions interested in pursuing the huge funding potential were all
salivating at the thought of all the grant money soon to flow into their
coffers with NO chance of patients ever benefitting. All the while, Don Margolis said many times
in many ways, “It will never happen!” “The embryonic lobby will never allow any
clinical trial to be held because they know that immune rejection by the
patient is possible and that, based on animal research, brain tumors may be
in the cards!” “That is why we at the Repair Stem Cell
Institute expect the embryonic lobby to pull its weight and stop this
potential catastrophe in the making. “ “For a listed company to cynically
manipulate stock prices and raise the hopes of sufferers as Geron does
regularly, might be considered a bit unethical.” In time,
Mr Margolis’ statements were proven conclusively when the efforts and agendas
of Geron, Wall Street and the FDA synchronized to hype the company on the false
promise of an FDA approved embryonic clinical trial. Misled investors donated $43 million to
Geron in a mid-February scam well documented by “TheStreet.com.” The
money is in the till, and there is no need to pretend any longer that a
clinical trial will be held. The
eleventh known Geron fraud is complete. |
|||||||
|
Mr.
Margolis concluded with uncanny accuracy: “The public, and spinal cord injury patients in particular, deserve
to know the facts and to be aware that right now patients are being helped,
and will be long after Geron’s trial is either yanked or fails.” There is only
one slight upside to this fiasco of criminal negligence where investors were
taken advantage of, spinal cord injury patients were given false hope and the
rampant misinformation of the general public continued. Embryonic stem cells used for treatment
have a history of turning into tumors.
To date, the only victims have been thousands of dead animals and one
or two human patients with tumors. The
original trial was to include 8-10 people with severe spinal cord injuries. So, with the trial on hold, that’s 8-10
people who will not have “tumors” or “death” added to their medical chart.” What you are about to read
here, you cannot read in a major city American newspaper. They are all --- every one --- a major
player in the embryonic hoax, as is the president, and most of Congress. But in Europe BRITISH EMBRYONIC LEADER TELLS IT LIKE IT AS THE EMBRYONIC HOAX
STARTS TO CRUMBLE UNDER THE PRESSURE OF TRUTH
Professor Colin McGuckin is professor of regenerative medicine
at Newcastle University, UK. His team was the first to characterize a
harvesting and culture strategy to produce embryonic stem cells from
umbilical cord blood, and the first to grow real liver tissue from umbilical
cord stem cells cultured in vitro, an important step toward replacing
liver transplants with new livers. In other words, a respected world-leader
in his field. Here is what the good doctor says: “The best estimates
of the embryonic scientists in our own university in Newcastle is that
embryonic stem cells may not be able to help people this side of 50 years.
That’s my lifetime. And that’s worrying. We can’t wait that long.” Prof.
McGuckin, unlike the embryonic researchers groping for tax money for research
to find cures which are so far in the future they are almost beyond
imagination, has put his future where his mouth is, assuming a key role in a
new European ADULT stem cell research organization, Novussanguis,
three months after his courageous exposure of the embryonic truth.
He is the highest ranking embryonic researcher to actually tell the truth
about the overhyped promise of embryonics.
From the Novussangus press release: Cord blood and adult stem cells are
very attractive for research in cell therapy and regenerative medicine
because of their high differentiation and expansion potential. Adult stem cells can be harvested from
several human tissues such as brain, bone marrow, peripheral blood, liver,
cornea, retina, and pancreas. It is also possible to find stem cells in
umbilical cord blood. With over 130 million births per year worldwide, cord
blood is a particularly important source of readily available stem cells in
terms of access and supply. Adult stem cells play a key role in
research for treatment of several diseases. Today, over 80 diseases are
treatable with cord blood stem cells, some linked to the blood system (e.g.
leukemia) or the immune system (‘babies in a bubble’)**, but also
neurological diseases (MS. CP, ALS), diseases affecting the bone marrow,
nervous system, heart or metabolism such as diabetes. **Coincidentally,
the unchallenged world-leader on this "bubble" malady is our own
Science Advisory Board Deputy Chairman, Prof. Shimon Slavin of Israel. A SECOND EMBRYONIC LEADER TELLS THE TRUTH
Scientists Admit Embryonic
Stem Cell Research Hasn't Been Successful
London,
England (LifeNews.com) -- While pro-life advocates have
repeated the mantra for years that embryonic stem cell research hasn't helped
a single patient while adult stem cells have already been used in humans
afflicted with dozens of diseases, a leading scientist in England is
beginning to admit defeat. Lord
Patel of Dunkeld, the chairman of the UK National Stem Cell Network and a
chancellor at Dundee University, says embryonic stem cell research is simply
not working. He conceded in an
interview with The Scotsman newspaper that the controversial science
may never deliver new treatments for diseases. "In terms of embryonic stem
cell therapy, there is currently no such therapy that is available in a large
number of patients," he said. Patel also admitted scientists may
never be able to overcome the hurdles -- such as the development of tumors or
immune syndrome rejection issues -- that plague embryonic stem cell research
and make it risky in humans. "We have to be cautious,"
he told the Scotsman.. "It may not deliver therapy for anything. We may
find that stem therapy is quite a risky business." "We had a lot of hype about
gene therapy, and while we still use it in some cases it did not deliver the
great promise we thought it would because of the side effects," he said. Despite downplaying the prospects
for success, Lord Patel told the newspaper he still thought embryonic stem
cell research should move forward. The newspaper also interviewed Dr.
Willy Lensch, from the Children's Hospital in Boston, who also confirmed the
possibility that the prospect of embryonic stem cell research may never play
out. "I could not guarantee to
anyone that this work will actually lead to improvements in disease as a
definite," he admitted. For American bioethics watchdog
Wesley Smith, the admissions aren't surprising. "For the last ten years, 'the
scientists,' in order to win the political debates over embryonic stem cell
research and [human cloning] often wildly hyped the potential for
cures," he said. "In the process, they convinced
Californians--now facing a $16 billion budget deficit and tens of billions in
bond debt--to borrow $300 million every year to pay for human cloning and
embryonic stem cell research," he explained. "States vied with each other
in an Oklahoma land race type scramble to throw money at Big Biotech. The
focus of the media became obsessed with overturning President Bush's funding
policy, to the point that it committed serial journalistic malpractice with
biased reporting and a news blockade on non-embryonic stem cell
successes," Smith added. "Well, those cures have not
even appeared as distant silhouettes on the horizon yet, and finally, a few
in the media are beginning to notice," Smith concluded. "By hyping the potential, the
politicized science sector misled people to win a political debate, and in
the process reduced science to just another special interest spinning and
obfuscating to get a greater share of gruel in the public trough." A THIRD EMBRYONIC COLLAPSE IN THE MOST EMBRYONIC-SUPPORTIVE COUNTRY
IN THE WORLD.
Embryonic Stem-Cell Firm
Abandons Efforts
Investors reportedly have lost interest in an embryonic stem-cell
research lab’s failed efforts to create clinical therapies, according to
the company’s former chief executive. Alan Colman, former chief executive of ES Cell International (ESI),
a leading Singapore biotechnology research firm, told Science magazine
that investors concluded that “the likelihood of having products in
the clinic in the short term was vanishingly small.” Dawn Vargo, associate bioethics analyst for Focus on the Family
Action, said the real promise of stem-cell treatments and therapies is in
adult stem cells, which do not involve the destruction of a human
life. “When prominent scientists in the field of embryonic stem-cell
research say that that they need ‘success stories,’ it's pretty obvious that
the real truth about embryonic stem-cell research is being revealed,” Vargo
said. “The truth is that embryonic stem-cell research has yet to yield a
single successful treatment for patients. Meanwhile, adult stem cells
continue to provide success stories – more than 70 diseases and ailments are
being treated and more than 1,500 clinical trials are using adult stem cells
for treatment.” COMMENT IT MUST BE NOTED HERE THAT NO GOVERNMENT IN THE WORLD HAS
BEEN MORE SUPPORTIVE OF ESC THAN THAT OF SINGAPORE.....Don Margolis A FOURTH ARTICLE BY A RESEARCH DOCTOR WHO ADMITS THAT SHE IS
ABSOLUTELY NOWHERE AND HASN'T DONE MUCH BESIDES KILL LAB ANIMALS AND KEEP THE
FAITH
Stem cell therapy shows
promise, problems
DANBURY -- The brave new world of
stem cell therapy -- where injected cells rush to the scene of damage or
disease in our bodies and provide a fix -- may still come true, but it is
years away. As researchers learn about stem cells, they are also learning about
the complications of an entirely new field of study. Yet the hope
persists. "Why do we care about stem cells?" Laura Grabel asked a
crowded lecture hall at Western Connecticut State University this week.
"Why is this room full of people? Why does every presidential candidate
feel it's necessary to give a position on stem cell research?" Grabel -- the Fisk Professor of Natural Sciences at Wesleyan
University in Middletown and one of the country's leading stem cell scientists
-- spoke at WestConn about her own work trying to learn if stem cells can
transform themselves into neurons, the body's nerve cells. But she also talked of some of the pitfalls of the research, and of
the broad philosophical and political issues that entangle themselves in the
work. Stem cells are the body's protean, shape-changing cells -- the
fertilized cells in the human embryo that split and differentiate themselves
to become all the organs and tissues of the body. The great hope of stem cell therapy is if you bring these cells to
injured parts of the body, they'll start reproducing and repair that
injury. The great problem at the very start
is that researchers need human embryos to do this work, and many people
believe these embryos -- which contain about 100 cells and have not yet
attached themselves to the walls of a woman's uterus -- are nevertheless
human life. Because of that, President Bush six years ago said that federal
funds could only be used to do research on the stem cell lines established at
that time. There are about 10 of those lines, Grabel said, and researchers
need more. "We need embryos," she said. To override the limits, some states have begun funding their own
research into stem cells. Connecticut will spend $10 million per year for 10
years on this work, and Grabel has received nearly $1 million of this grant
money. Grabel said private companies also fund the research, but some of
them have walked away. "There isn't a lot of money or a lot of eggs available. Because
things aren't happening more quickly, some private companies are closing
down," Grabel said. Ongoing research is complicated. Grabel said in one project
at Wesleyan, she and her colleagues injected a solution into mice that causes
epilepsy, causing the death of some brain neurons. They then injected neural stem cells -- stem cells that are in the
process of producing neurons -- into the mice to see if they'd migrate to the
damaged areas and repair them. Instead, they headed to another section of the
brain that is responsible for producing new neurons. "I think they wanted to go where the signals for new growth
are," Grabel said. Knowing that may help researchers manipulate those
signals -- and stem cells -- in the future. Grabel said when mice without epilepsy damage got the stem cells,
about 80 percent developed tumors. Many of the tumors contained
undifferentiated stem cells -- cells that could grow into different body
parts -- rather than neural stems cells, which could only grow into
neurons. "That means we screwed up somewhere," Grabel said. There are many issues -- tumor production, genetic compatibility,
generating the right types of cells for transplant, making sure the stem
cells aren't contaminated -- that scientists must face in this
research. While they get resolved, the moral, ethical and political winds
continue to blow. Grabel said despite great hopes, two other forms of stem cells --
adult stem cells and umbilical stem cells -- don't offer the same potential
as embryos. But she also acknowledged great potential for using stem cells to
treat any number of diseases, including Type 1 diabetes, multiple sclerosis
and Alzheimer's. There has already been definite progress in treating
Parkinson's disease and spinal cord injuries in animal models using stem
cells. "But even for them, we're
talking about being years and years away from treating humans," she
said. "For things like epilepsy, it's even further away." |
||||||||
|
Advertisements
|
||||||||
|
Contact USA Direct Line: |
Don Margolis, Chairman |
|||||||
|
www.repairstemcells.com |
www.donrmargolis.com |
|||||||
|
LEGAL DISCLAIMER This Newsletter is for
educational purposes only and not to be taken as medical advice. |
||||||||
